Cargando…
Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts
Non-small cell lung cancer (NSCLC) is commonly diagnosed at advanced stages limiting treatment options. Although, targeted therapy has become integral part of NSCLC treatment therapies often fail to improve patient’s prognosis. Based on previously published criteria for selecting drug combinations f...
Autores principales: | Gürgen, Dennis, Conrad, Theresia, Becker, Michael, Sebens, Susanne, Röcken, Christoph, Hoffmann, Jens, Langhammer, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763947/ https://www.ncbi.nlm.nih.gov/pubmed/35039644 http://dx.doi.org/10.1038/s42003-022-03016-5 |
Ejemplares similares
-
Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC
por: Langhammer, Stefan, et al.
Publicado: (2017) -
Impact of the Monocarboxylate Transporter-1 (MCT1)-Mediated Cellular Import of Lactate on Stemness Properties of Human Pancreatic Adenocarcinoma Cells †
por: Sandforth, Leontine, et al.
Publicado: (2020) -
The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-β1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-β1
por: Genrich, Geeske, et al.
Publicado: (2016) -
A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies
por: Gürgen, Dennis, et al.
Publicado: (2022) -
Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity
por: Shih, Hung-Ju, et al.
Publicado: (2012)